查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870380

抗感染劑市場按產品類型、適應症、給藥途徑、分銷管道和最終用戶分類－2025-2032年全球預測

Anti-infectives Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗感染劑市場規模將達到 1,997.3 億美元，年複合成長率為 5.36%。

關鍵市場統計數據
基準年 2024 1314.3億美元
預計年份：2025年 1383.7億美元
預測年份 2032 1997.3億美元
複合年成長率 (%) 5.36%

為策略決策者提供全面的抗感染領域概覽，以明確臨床、營運、監管和創新方面的優先事項。

抗感染領域處於公共衛生迫切需求與複雜商業性動態的交會點，臨床需求與供應鏈現實和快速發展的科學成果在此碰撞交織。本導論透過確立影響產業界、醫療保健界和政策制定者決策的關鍵主題支柱，闡明了這種交會點。它重點闡述了應對抗菌素抗藥性和確保持續獲得​​現有及新型治療方法的雙重挑戰，摘要了決定近期優先事項的結構性、臨床和監管治療方法，並引導讀者閱讀以下各章節。

快速診斷技術、新型治療方法和彈性供應鏈策略如何重塑抗感染領域的臨床決策和商業模式

抗感染領域正經歷深刻的變革時期，科學、商業性和製度層面的變革同步發生。精準診斷和快速分子檢測技術的進步使得更早、更有針對性的治療方案成為可能，從而改變了處方模式和對特定藥物類別的需求。同時，創新正從漸進式改善加速發展，轉向針對抗藥性病原體的新型治療方法和基於機制的療法，並在生物製藥公司、診斷開發商和臨床網路之間催生出新的合作模式。因此，價值鏈正從以產品為中心的模式演變為提供整合治療、診斷、管理計畫和數位化監測平台的解決方案。

評估截至2025年累積關稅調整對整個抗感染價值鏈的籌資策略、營運韌性和投資決策的淨影響

到2025年，累積貿易政策措施和關稅調整正在影響整個抗感染供應鏈的成本結構和策略規劃，尤其是那些依賴跨境採購中間體和成品的公司。雖然關稅政策並非對所有治療領域都適用，但其累積效應提高了人們對單一供應商依賴性脆弱性的認知，並加速了減少對地理位置集中供應商依賴的步伐。因此，採購團隊和生產負責人越來越重視供應商多元化、建立本地生產能力以及透過合約保護來應對關稅不確定性。

綜合細分分析重點在於治療類別、臨床適應症、給藥途徑、分銷管道和最終用戶對差異化策略的影響

細緻的市場細分框架揭示了臨床需求、產品屬性和分銷管道動態相互作用，從而形成差異化策略重點的領域。基於產品類型的分類涵蓋了抗生素、抗真菌藥物、抗寄生蟲藥和抗病毒藥等廣泛類別。在抗生素領域，Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類、磺胺類藥物和四環黴素是策略重點領域，每種藥物都有不同的抗藥性特徵和合理用藥挑戰。抗真菌藥物包括Allylamines、Azole、Echinocandins和Polyenes，它們在抗菌頻譜、毒性特徵以及住院與門診病人用藥方面存在差異。抗寄生蟲藥包括驅蟲藥、抗瘧疾藥和抗原生動物藥，其需求模式受區域流行病學的影響。同時，抗病毒藥物包括神經氨酸酶抑制劑、核苷類似物、聚合酵素抑制劑和蛋白酶抑制劑，這反映了其作用機制的多樣性以及慢性病和急性疾病的使用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對抗藥性流感病毒株的新型口服小分子抗病毒藥物
  • 在門診細菌感染疾病治療中快速引入長效注射抗生素
  • 將人工智慧驅動的預測診斷技術應用於醫院，以最佳化抗生素管理
  • 增加噬菌體療法平台的投資，以對抗多重抗藥性細菌的出現
  • 在念珠菌症負擔沉重的新興市場，擴大新型抗真菌藥物的全球准入計劃

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型抗感染劑市場

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺類
    • Fluoroquinolones
    • 大環內酯類
    • 磺胺類藥物
    • 四環黴素
  • 抗真菌藥物
    • Allylamines
    • Azole
    • Echinocandins
    • Polyenes
  • 抗寄生蟲藥物
    • 驅蟲藥
    • 抗瘧疾藥
    • 抗原生動物藥物
  • 抗病毒藥物
    • 神經氨酸酶抑制劑
    • 核苷類似物
    • 聚合酵素抑制劑
    • 蛋白酶抑制劑

第9章 依適應症分類的抗感染劑市場

  • 血液感染疾病
  • 胃腸道感染疾病
  • 呼吸道感染疾病
    • 支氣管炎
    • 社區型肺炎
    • 院內肺炎
  • 皮膚和軟組織感染疾病
  • 尿道感染

第10章 按給藥途徑分類的抗感染劑市場

  • 吸入
  • 口服
  • 腸外給藥
  • 局部用藥

第11章 按分銷管道分類的抗感染劑市場

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的抗感染劑市場

  • 診所
  • 居家醫療環境
  • 醫院

第13章 各地區的抗感染劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章抗感染劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國抗感染劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Roche Holding AG
    • Johnson & Johnson
    • Sanofi SA
    • AstraZeneca plc
    • Novartis AG
    • Bayer Aktiengesellschaft
    • Astellas Pharma Inc.
Product Code: MRR-1A1A064C0031

The Anti-infectives Market is projected to grow by USD 199.73 billion at a CAGR of 5.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 131.43 billion
Estimated Year [2025] USD 138.37 billion
Forecast Year [2032] USD 199.73 billion
CAGR (%) 5.36%

Comprehensive framing of the anti-infectives landscape to clarify clinical, operational, regulatory, and innovation priorities for strategic decision-makers

The anti-infectives domain stands at the intersection of urgent public health need and complex commercial dynamics, where clinical imperatives collide with supply chain realities and rapid scientific progress. This introduction frames that convergence by establishing the critical thematic pillars that shape decision-making across industry, healthcare providers, and policy sponsors. It highlights the dual challenge of addressing antimicrobial resistance while ensuring resilient access to established and novel therapies, and it orients readers toward the sections that follow by summarizing the structural, clinical, and regulatory forces that will determine near-term priorities.

In the current environment, stakeholders must balance short-term operational responses with mid- to long-term strategic investments. Accordingly, this section positions the narrative around four core dimensions: therapeutic innovation and repurposing, manufacturing and procurement resilience, regulatory and market access dynamics, and integrated diagnostic stewardship. These dimensions serve as the lenses through which subsequent analyses of segmentation, regional differences, company strategy, and policy impacts should be interpreted. By clarifying the interplay among scientific advances, distribution channels, and care settings, this introduction prepares leaders to translate evidence into prioritized action.

Finally, the introduction emphasizes evidence-driven decision-making and cross-sector collaboration as foundational principles. It underscores the necessity of linking clinical practice with supply chain design and market intelligence, thereby creating a consistent frame for the deeper insights and recommendations presented in the rest of the executive summary.

How rapid diagnostics, novel therapeutic modalities, and resilient supply chain strategies are reshaping clinical decision making and commercial models across anti-infectives

The anti-infectives landscape is being reshaped by transformative shifts that are simultaneously scientific, commercial, and systemic. Advances in precision diagnostics and rapid molecular testing are enabling earlier and more targeted therapeutic choices, which in turn alter prescribing patterns and demand for specific classes of agents. At the same time, innovation has accelerated beyond incremental modifications toward novel modalities and mechanism-based therapies that address resistant pathogens, creating new partnership models between biopharma, diagnostic developers, and clinical networks. As a result, value chains are evolving from product-centric models to integrated solution offerings that combine therapeutics with diagnostics, stewardship programs, and digital monitoring platforms.

Concurrently, supply chain strategies are undergoing structural rebalancing. Stakeholders are increasingly prioritizing manufacturing flexibility, dual sourcing of critical active pharmaceutical ingredients, and strategic inventory policies to mitigate geopolitical and logistics risks. Regulatory environments are adapting to these shifts through expedited pathways for clinically urgent agents and greater emphasis on real-world evidence to support treatment decisions. Market access pressures are also stimulating new contracting approaches, including indication-specific agreements and outcome-based pricing that align incentives for appropriate use.

Taken together, these transformational changes are creating opportunities for nimble organizations to differentiate through integrated offerings, durable manufacturing strategies, and closer alignment with clinical workflows. The net effect is a more interconnected ecosystem in which scientific innovation, operational resilience, and data-driven market access strategies determine competitive positioning and public health impact.

Assessment of how cumulative tariff adjustments through 2025 have materially influenced sourcing strategies, operational resilience, and investment decisions across the anti-infectives value chain

Cumulative trade policy measures and tariff adjustments enacted through 2025 have influenced cost structures and strategic planning across the anti-infectives supply chain, particularly for firms reliant on cross-border sourcing of intermediates and finished products. While tariff policy does not uniformly apply to all therapeutic categories, its cumulative effect has been to raise awareness of single-source vulnerabilities and to accelerate initiatives that reduce dependence on geographically concentrated suppliers. Consequently, procurement teams and manufacturing executives have increasingly prioritized supplier diversification, localized capacity building, and contractual protections to manage tariff-driven uncertainty.

Moreover, tariff-related pressures have shifted the calculus for capital investment and partnership formation. Companies evaluating new manufacturing sites or expansion projects must now weigh potential tariff exposure alongside labor, regulatory, and logistics considerations. At the same time, some firms have pursued strategic vertical integration or established closer contractual relationships with contract development and manufacturing organizations to buffer against external trade shocks. These responses reflect an operational pivot toward resilience rather than solely cost minimization.

Finally, regulatory and policy responses to tariff pressures have introduced additional considerations. In many jurisdictions, policymakers have shown a willingness to implement targeted exemptions or engagement programs to preserve access to essential medicines, which has moderated some of the immediate impacts for critical items. Nevertheless, the cumulative impact through 2025 remains a material factor in procurement strategy, supply chain design, and financial planning across the anti-infectives ecosystem, prompting sustained emphasis on scenario planning and adaptive sourcing frameworks.

Integrated segmentation analysis revealing therapeutic classes, clinical indications, administration routes, distribution channels, and end-user implications for differentiated strategy

A nuanced segmentation framework illuminates where clinical need, product characteristics, and channel dynamics interact to create differentiated strategic priorities. Based on product type, the field spans broad classes such as antibiotics, antifungals, antiparasitics, and antivirals; within antibiotics, strategic focus areas include aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines, each with distinct resistance profiles and stewardship implications. The antifungal segment includes allylamines, azoles, echinocandins, and polyenes, which vary by spectrum of activity, toxicity profiles, and inpatient versus outpatient application. Antiparasitics cover anthelmintics, antimalarials, and antiprotozoals, with regional epidemiology driving demand patterns, while antivirals encompass neuraminidase inhibitors, nucleoside analogues, polymerase inhibitors, and protease inhibitors, reflecting diverse mechanisms and both chronic and acute use cases.

Based on indication, the market separates along clinical presentations such as bloodstream infections, gastrointestinal infections, respiratory infections, skin and soft tissue infections, and urinary tract infections; respiratory infections further distinguish bronchitis, community-acquired pneumonia, and hospital-acquired pneumonia, each of which involves unique diagnostic pathways and settings of care. Based on route of administration, therapeutic choices are organized by inhalation, oral, parenteral, and topical delivery, which influence prescribing patterns, adherence considerations, and distribution logistics. Based on distribution channel, medicines are delivered through drug stores, hospital pharmacies, online pharmacies, and retail pharmacies, with each channel presenting different reimbursement dynamics and patient access considerations. Based on end user, adoption and purchasing behavior diverge across clinics, home care settings, and hospitals, shaping contracting strategies, clinical training needs, and point-of-care diagnostics integration.

Integrating these segmentation layers reveals priority intersections where development investment, commercial focus, and supply chain resilience yield the greatest strategic return. For example, agents intended for hospital-acquired respiratory infections that require parenteral administration will necessitate robust hospital pharmacy alignment and inpatient stewardship programs, whereas oral antivirals for outpatient care will prioritize retail and online pharmacy distribution, adherence solutions, and payer engagement.

Comparative regional dynamics highlighting how epidemiology, manufacturing ecosystems, regulatory approaches, and healthcare financing shape differentiated strategic priorities

Regional dynamics shape the anti-infectives environment by aligning epidemiology, manufacturing capacity, regulatory approaches, and payer behavior in distinct patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems combine advanced hospital capabilities with large outpatient markets and established generics manufacturing, creating demand for both novel therapeutics and optimized procurement strategies that preserve access. Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied healthcare financing models and a pronounced emphasis on antimicrobial stewardship, which influences formulary decisions and reimbursement pathways.

In the Asia-Pacific region, rapid expansion of manufacturing capacity, strong generics competitiveness, and shifting R&D investment are key features; these dynamics are coupled with heterogeneous regulatory systems and varying levels of healthcare infrastructure, which together drive both export-oriented production and growing regional demand for innovative treatments. Transitional economies within these regions are shaping procurement models that balance cost containment with the need to upgrade clinical diagnostics and supply chain resilience. Across all regions, cross-border collaboration on surveillance and resistance monitoring is increasingly important, and regional policy initiatives often determine priority access for specific therapeutic classes.

Taken together, these regional insights emphasize that strategies must be tailored to local regulatory norms, manufacturing ecosystems, and clinical practice patterns. Companies that align product formulation, distribution models, and stewardship partnerships to regional realities will be better positioned to achieve sustained clinical adoption and resilient supply operations.

Strategic behaviors and competitive positioning of established pharmaceutical firms, generics manufacturers, biotech innovators, and contract manufacturers shaping future leadership

Company trajectories within anti-infectives are diverging as traditional pharmaceutical firms, generics leaders, biotech innovators, and contract manufacturers adopt differentiated strategies to capture clinical and commercial value. Established large-pharma players are leveraging broad portfolios, regulatory experience, and global distribution networks to support late-stage clinical programs and to maintain supply continuity for essential lines. Conversely, generics manufacturers and specialized chemical producers are concentrating on cost-efficient production, scale in active pharmaceutical ingredients, and rapid response to demand spikes, making them pivotal partners for supply security.

Biotech and small-cap innovators are focusing on novel mechanisms of action, narrow-spectrum agents, and adjunctive therapies that enable more targeted approaches to resistant pathogens. These firms frequently engage in partnerships with diagnostic companies and clinical networks to demonstrate value through precision prescribing. Contract development and manufacturing organizations are expanding capabilities to offer flexible, small-batch production and regulatory support, thereby enabling faster commercialization for both emergent agents and reformulated legacy products. Across company types, M&A, licensing, and co-development agreements are being used strategically to bridge R&D gaps, secure manufacturing footprint, and accelerate access to complementary technologies.

In sum, competitive advantage is increasingly derived from the ability to integrate clinical differentiation with operational resilience and payer-aware commercial models. Firms that combine targeted innovation with supply chain agility and strong clinical evidence generation are positioned to lead, while those that lag in diagnostic integration or flexible manufacturing risk erosion of market relevance.

Practical strategic imperatives for industry leaders to align diagnostics, stewardship, flexible manufacturing, and evidence-based contracting for sustainable advantage

Industry leaders should prioritize a set of high-impact actions that align clinical value with operational resilience and commercial viability. First, integrate rapid diagnostics and stewardship programs with therapeutic rollouts to ensure that new and existing agents are used effectively and sustainably, thereby preserving long-term clinical utility. Second, diversify sourcing and invest in manufacturing flexibility to mitigate geopolitical and tariff-related risks while preserving cost competitiveness; contractual mechanisms and strategic partnerships can accelerate this transition. Third, adopt indication- and outcome-based contracting models with payers and health systems to align incentives for appropriate use and to demonstrate real-world value.

Further, invest selectively in novel mechanisms and platform technologies that address resistant pathogens, while leveraging strategic alliances for accelerated clinical development and market entry. Commit to comprehensive surveillance and data-sharing initiatives that support both public health objectives and commercial decision-making, enabling more precise targeting of clinical trials and post-market evidence generation. Finally, ensure organizational readiness through cross-functional governance that links R&D, regulatory affairs, supply chain, and commercial teams to expedite decision cycles and reduce time-to-clinic or time-to-market for priority assets.

By implementing these actions in a coordinated manner, leaders can balance short-term access imperatives with long-term stewardship and innovation goals, transforming systemic challenges into sources of competitive advantage.

Robust mixed-methods research approach combining primary interviews, regulatory and clinical literature review, case studies, and scenario mapping to validate insights

The research methodology underpinning this analysis combines multi-source evidence, expert input, and structured synthesis to deliver actionable insights. Primary research included in-depth interviews with senior executives across pharmaceutical, biotech, manufacturing, and clinical backgrounds, supplemented by consultations with regulatory specialists and supply chain practitioners to validate operational implications. Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, clinical treatment guidelines, and publicly available corporate disclosures to contextualize trends and triangulate findings.

Analytical approaches incorporated qualitative thematic analysis and scenario-based supply chain mapping to explore how policy changes, tariff dynamics, and clinical innovation could interact under alternative conditions. Case studies were used to illustrate best practices in manufacturing resilience, diagnostic-therapeutic integration, and stewardship program implementation. Finally, internal expert panels reviewed draft findings to ensure relevance for commercial strategy and to refine recommendations according to operational feasibility and regulatory realities.

This mixed-methods approach emphasizes transparency, triangulation, and practitioner validation, providing stakeholders with a robust evidence base for strategic planning without relying on proprietary forecasting that could obscure operational nuances.

Concluding synthesis that balances urgent resilience measures with long-term innovation and stewardship priorities to guide strategic investment and policy engagement

In conclusion, the anti-infectives sector is undergoing a period of substantive transformation driven by diagnostic advances, evolving supply chain imperatives, and strategic shifts in innovation models. These forces are creating both challenges and opportunities: challenges in the form of resistance dynamics, procurement complexity, and policy uncertainty; and opportunities in the form of integrated diagnostic-therapeutic solutions, resilient manufacturing partnerships, and novel commercial models that align clinical value with payment outcomes. The synthesis presented here highlights where to focus resources to preserve access and to deliver differentiated therapeutic value.

Organizations that proactively integrate stewardship with go-to-market strategies, diversify their manufacturing and sourcing footprint, and build evidence generation frameworks aligned with payer expectations will be best positioned to navigate the evolving landscape. Collaboration across public and private stakeholders, investment in flexible production capabilities, and commitment to targeted R&D will be essential to ensuring sustained patient access and long-term therapeutic effectiveness. The recommendations in this summary are designed to be operationally actionable and to support decision-makers as they translate insight into measurable strategic moves.

Ultimately, the path forward requires balancing near-term operational resilience with long-term investments in innovation and stewardship, ensuring that therapeutic advances are preserved and widely accessible for the populations that need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of novel oral small molecule antivirals targeting resistant influenza strains
  • 5.2. Rapid adoption of long-acting injectable antibiotics for outpatient management of bacterial infections
  • 5.3. Integration of AI-driven predictive diagnostics to optimize antibiotic stewardship in hospitals
  • 5.4. Rising investment in phage therapy platforms to address multi-drug resistant bacterial outbreaks
  • 5.5. Expansion of global access programs for novel antifungal agents in emerging markets experiencing high candidiasis burden

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Allylamines
    • 8.2.2. Azoles
    • 8.2.3. Echinocandins
    • 8.2.4. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Anthelmintics
    • 8.3.2. Antimalarials
    • 8.3.3. Antiprotozoals
  • 8.4. Antivirals
    • 8.4.1. Neuraminidase Inhibitors
    • 8.4.2. Nucleoside Analogues
    • 8.4.3. Polymerase Inhibitors
    • 8.4.4. Protease Inhibitors

9. Anti-infectives Market, by Indication

  • 9.1. Bloodstream Infections
  • 9.2. Gastrointestinal Infections
  • 9.3. Respiratory Infections
    • 9.3.1. Bronchitis
    • 9.3.2. Community Acquired Pneumonia
    • 9.3.3. Hospital Acquired Pneumonia
  • 9.4. Skin And Soft Tissue Infections
  • 9.5. Urinary Tract Infections

10. Anti-infectives Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
  • 10.4. Topical

11. Anti-infectives Market, by Distribution Channel

  • 11.1. Drug Stores
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Anti-infectives Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Roche Holding AG
    • 16.3.5. Johnson & Johnson
    • 16.3.6. Sanofi S.A.
    • 16.3.7. AstraZeneca plc
    • 16.3.8. Novartis AG
    • 16.3.9. Bayer Aktiengesellschaft
    • 16.3.10. Astellas Pharma Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY